LANSING, Mich., Aug. 19, 2015 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“Company”), the leading developer of advanced spider silk based fibers, announced that it, with the University of Notre Dame, filed two additional patents to strengthen its intellectual property protection surrounding its transgenic silkworms and spider silk technologies.
These patent applications are designed to protect the creation of the Kraig Labs transgenic silkworms and the resultant chimeric spider silk. The Company currently has open patent actions in 10 countries, including key silk producer and consumer nations.
“From our inception, Kraig Labs has remained dedicated to a spirit of innovation and refused to accept can’t as an answer,” said Company Founder and CEO, Kim Thompson. “This pursuit of the seemingly impossible led to a series of first of its kind inventions, including our recently announced Dragon Silk™ genetic line. The filling of these two additional patents seeks to protect the creativity and value of that work for Kraig Labs and our shareholders, and goes hand in hand with our commercial market development plans.”
About Kraig Biocraft Laboratories, Inc.
Kraig Biocraft Laboratories, Inc. (www.KraigLabs.com), a fully reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies. The Company has achieved a series of scientific breakthroughs in the area of spider silk technology with implications for the global textile industry.
Cautionary Statement Regarding Forward Looking Information
Statements in this press release about the Company’s future and expectations other than historical facts are “forward-looking statements.” These statements are made on the basis of management’s current views and assumptions. As a result, there can be no assurance that management’s expectations will necessarily come to pass. These forward-looking statements generally can be identified by phrases such as “believes,” “plans,” “expects,” “anticipates,” “foresees,” “estimated,” “hopes,” “if,” “develops,” “researching,” “research,” “pilot,” “potential,” “could” or other words or phrases of similar import. Forward looking statements include descriptions of the Company’s business strategy, outlook, objectives, plans, intentions and goals. All such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those in forward-looking statements.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any security.
Ben Hansel, Hansel Capital, LLC. (720) 288-8495 ir@KraigLabs.com
Source:Kraig Biocraft Laboratories, Inc